J&J's Tremfya Takes on Crohn's Hardest Frontier in IL-23 Battle

BEERSE, BELGIUM – October 19, 2026 – In the high-stakes chess match of 21st-century biopharma, clinical data is the currency of market dominance. Today, Johnson & Johnson Innovative Medicine added substantial capital to its ledger, unveiling new Phase 3 data for Tremfya (guselkumab) at the 2026 United European Gastroenterology (UEG) Week. By presenting three-year maintenance outcomes in moderate to severe Crohn’s disease alongside 48-week results in perianal fistulizing Crohn’s disease, the healthcare giant is not merely updating a medical label; it is executing a calculated maneuver to outflank its rivals in the lucrative immunology sector.

Crohn’s disease affects an estimated two million people across Europe. For decades, the therapeutic ceiling was defined by short-term symptom management. Now, the battlefield has shifted toward long-term, durable disease control. But as the global business landscape adapts to these advanced biological therapies, the structural changes reshaping the marketplace demand a forensic look at how these clinical victories are framed, contested, and ultimately commercialized.

Tackling Crohn's Hardest Frontier

To understand the strategic rationale behind Tremfya’s latest data drop, one must look at the specific patient population the company is targeting. The Phase 3 FUZION study focuses on perianal fistulizing Crohn’s disease, a devastating complication where abnormal channels form between the bowel and the skin. Up to 40 percent of patients with Crohn’s disease will develop fistulas, which are notoriously refractory to standard medical treatments and frequently require invasive surgical interventions.

Historically, gastroenterologists have relied on anti-TNF therapies like infliximab to manage fistulas, often with mixed long-term success. By generating dedicated, randomized, placebo-controlled Phase 3 data in this specific cohort, Johnson & Johnson is driving a wedge into an area of immense unmet clinical need. The 48-week FUZION findings show that combined fistula remission—incorporating both clinical and radiological assessments—increased from 28 percent at Week 24 to 35 percent at Week 48 in the 100 mg every eight weeks dose group.

"Perianal fistula remains one of the most debilitating complications of Crohn's disease, where achieving durable disease control beyond symptom improvement is a challenge," said Ailsa Hart, Ph.D., Director of St Mark's Hospital Inflammatory Bowel Disease Research, Consultant Gastroenterologist, and study investigator. "The latest findings from the FUZION study show that patients treated with guselkumab maintained or improved upon the clinical benefits observed at Week 24, providing encouraging evidence for its use in this patient population."

This is a masterclass in market positioning. By establishing Tremfya as the only IL-23 inhibitor with this specific, dedicated trial design for fistulizing disease, the manufacturer provides a compelling rationale for physicians to choose its drug over competitors when faced with complex, difficult-to-treat manifestations.

The High-Stakes IL-23 Rivalry

The broader context of these announcements is the fierce commercial rivalry within the IL-23 inhibitor class, a highly competitive arena currently dominated by AbbVie’s Skyrizi (risankizumab) and increasingly contested by Lilly’s Omvoh (mirikizumab). As the industry transitions away from older biologics, securing formulary status and physician preference hinges on demonstrating superior, long-lasting efficacy.

Tremfya’s mechanism of action is central to its competitive narrative. Like Skyrizi, it targets the p19 subunit of IL-23, a cytokine known to drive immune-mediated diseases. However, Johnson & Johnson frequently highlights Tremfya’s unique ability to bind to CD64, a receptor on cells that produce IL-23. The theoretical implication is that this dual action enhances the drug's potency in neutralizing IL-23 signaling at the source.

Yet, a forensic reading of the fine print reveals a critical caveat. The press release acknowledges that findings for this unique mechanism of action are limited to in vitro studies, and the clinical significance remains unknown. In the cutthroat world of pharmaceutical marketing, theoretical advantages must eventually translate into undeniable clinical superiority.

"The IL-23 space is incredibly crowded, and every manufacturer is looking for a unique hook," noted one independent immunology researcher tracking the UEG Week data. "While the CD64 binding is a fascinating biological narrative, payers and prescribers are ultimately going to make their decisions based on hard clinical endpoints, mucosal healing, and long-term safety profiles, not just in vitro receptor affinities."

Reading Between the Percentages: The 'As-Observed' Caveat

This brings us to the headline-grabbing statistics from the Phase 3 GALAXI studies. It was reported that up to 94 percent of patients on the 100 mg maintenance dose achieved clinical remission at three years (Week 144), alongside endoscopic remission rates of up to 52 percent. On the surface, these numbers suggest a near-total victory over a chronic, progressive disease.

"The treatment goals in Crohn's disease continue to evolve beyond short-term symptom management towards achieving durable disease control that can be sustained over years," said Mark Graham, Therapeutic Area Head, Immunology, J&J Innovative Medicine EMEA. This sentiment was echoed by Prof. Silvio Danese, Gastroenterologist at Vita-Salute San Raffaele University, who noted, "In a chronic condition such as Crohn's disease, maintaining remission is as important as achieving it."

However, structural changes in how trial data is reported demand rigorous scrutiny. The 94 percent figure is derived from an "as-observed" analysis. This statistical method only includes patients who remained in the study and had data available at Week 144. It explicitly excludes participants who discontinued treatment, lacked data, or required a dose adjustment.

When we look at the broader picture, the overall treatment retention rate in the GALAXI trial was 74 percent through three years. This means that 26 percent of the initial patient cohort dropped out—a common occurrence in chronic disease trials due to adverse events, lack of efficacy, or logistical hurdles. Patients in the GALAXI studies received either 100 mg administered subcutaneously every eight weeks or a 200 mg dose every four weeks. Interestingly, both regimens showed robust efficacy, with the 200 mg dose demonstrating a slight edge in endoscopic remission (61 percent versus 52 percent). For healthcare payers, however, the nuances between these dosing schedules—and their associated costs—will be heavily scrutinized as they determine formulary placements.

"Reporting as-observed data is standard practice for long-term extensions, but it inherently inflates the perception of efficacy," explained an independent biostatistician familiar with gastroenterology trial designs. "If you applied a strict Intention-to-Treat or Non-Responder Imputation analysis—where every patient who drops out is counted as a treatment failure—that 94 percent remission rate would drop significantly. It is crucial for healthcare leaders and payers to contextualize these percentages against the 26 percent attrition rate."

Despite these statistical nuances, the data solidifies Tremfya’s position as a formidable long-term therapy. The safety profile remained consistent with known parameters, primarily featuring respiratory tract infections and injection site reactions, without revealing new long-term red flags.

As the biological therapeutics market continues to mature, the battle lines are no longer drawn merely at Week 12 induction endpoints. The future of competition in Crohn's disease relies on multi-year durability, proven efficacy in the most debilitating disease manifestations, and the strategic framing of clinical data. Johnson & Johnson has clearly signaled its intent to lead on all three fronts, setting a new benchmark that its rivals will now be forced to answer.